Global Contract Research Organization (CRO) Services Market is poised to witness a lucrative CAGR of 8% to reach $110 billion by 2026

The penetration level of outsourcing to CROs varies across the functions and is highest in the laboratory testing, clinical trial, and post-approval stages compared to discovery and pre-clinical stages. The outsourcing percentage is proportional to the complexity and regulatory expertise required at each stage. Some of the typical reasons why the pharmaceutical, biotechnology, and medical devices industries outsource to CROs include the following:

  • Better return on R&D investments
  • Lack of internal capabilities (esp. small biopharma companies)
  • Increasing complexity in developing targeted therapeutic areas like immuno-oncology therapies
  • Stringent regulatory requirements
  • Time and cost-efficiency

Covid-19 Impact: Increasing Attention on Virtual Clinical Trials

CROs are proactively converting site activity to decentralized/virtual trials, where possible, to maintain the integrity and regulatory compliance of ongoing studies.

“COVID-19 has necessitated the rapid uptake of a decentralized clinical trial approach to monitoring clinical trials. There was a brief period where, with the pandemic happening, most companies were faced with a huge stop in their clinical trial activities, which required rethinking, retooling, and re-strategizing how best to re-engage these sites with the clinical trials that they have currently ongoing.” - Former Division Leader, Industry-Leading CRO, US

Shifting Market Trend Towards Full-service CROs/One-stop-shop Model

Due to the complexities intrinsic to drug development, biopharma companies look for a full-service CRO offering across the drug development lifecycle. Apart from the breadth of services (pre-clinical, clinical, and commercialization), the trend is toward CROs offering scalable services, specialized technologies, and having a global presence.

Increasing Complexity of Therapeutics and Clinical Trials

The global CRO services market is witnessing the constantly rising complexity of clinical trials and targeted therapeutic areas (like oncology, CNS, cardiovascular, diabetes), making them more expensive and difficult to develop in-house. Moreover, evolving regulatory environment and burdensome penalties for non-compliance add to the duration, cost, and complexity of drug development, making it more lucrative to outsource.

Competitive Landscape Analysis: Global CRO Services Market

The CRO market has undergone intense consolidation over the last decade, shifting from a highly fragmented market to a fairly consolidated landscape currently. This trend is mainly driven by the demand of big pharma to partner with fewer full-service CROs. Some of the key players operating in CRO services market are IQVIA, Labcorp, Syneos Health, Thermo Fisher Scientific, Parexel, ICON, Charles River, WUXI Apptec, Pharmacon Beijing, SGS, among others.

Get Customized Research Report on CRO Services Market @ https://meditechinsights.com/contract-research-organization-cro-services-market/

Comments

Post a Comment

Popular posts from this blog

Global Healthcare Companion Robots Market valued at about $3 billion (2020), is growing at a lucrative CAGR close to 20% through 2020-2025

Companion robots offer companionship and emotional support for the children, elderly, and disabled people. Over the years, the improvements in sensors, actuators, and AI have led to rise in interest in healthcare companion robots market. Rising aging population, the rising cost of elder care, and shortage of caregivers The population across the globe is aging and the number of caregivers in relation to the aging population is declining. In Japan, there will be an estimated shortage of 1 million caregivers by 2025. Moreover, the cost of elder care is also rising. Between 2019 and 2020, the cost of in-home care jumped by about 4.4%; assisted living costs surged by 6.2%; and nursing home costs increased by 3%. The use of robots instead could help reduce this cost. For instance, a monthly service contract for Stevie (a robot developed by Trinity College, Dublin) would likely run between 50-60% of the cost of hiring a human to do the same tasks, as per their claim. “The growing dispar...
Read more

Global Mycoplasma Testing Market is slated to see a lucrative growth rate of 11% by 2027

Mycoplasmas are the smallest known free-living microorganisms and are frequent contaminants of mammalian cell cultures. For the safety and purity of vaccines and other biological cell-derived products, it is crucial that the cell substrates and unprocessed bulk materials are free of adventitious agents, including mycoplasma.  In many cases, mycoplasmas vary from other forms of bacteria, making them difficult to culture and identify. Testing is done to detect mycoplasma like Mycoplasma hominis, Mycoplasma genitalium, Mycoplasma pneumoniae, and Ureaplasma urealyticum which can cause nongonococcal urethritis (NGU), prostate inflammation (prostatitis), vaginal discharge, and pelvic inflammatory disease (PID) in both men and women. Rising Concerns of Cell Culture Contamination to Trigger the Growth of the Global Mycoplasma Testing Market Mycoplasmas randomly contaminate the fluids used in the bioprocessing and cell culture. It is commonly known that primary cell cultures have a minimum...
Read more

Global Obesity Drugs Market valued at $2.3 billion in 2022, is expected to Witness a Healthy Growth of 25% by 2027

Obesity and overweight are defined as gain of additional fat thus leading to a number of diseases, which can be measured by using body mass index (BMI) as a baseline. A BMI of over 30 is generally considered as obese and a BMI of over 25 is considered as overweight. Obesity is a major risk factor to various diseases such as diabetes, heart diseases, and cancer; approximately over 650 million obese patients living across the world as as projected by World Health Organization (WHO). Rising Obese and Overweight Population to Trigger the Demand of Obesity Drugs Market Obesity is one of the topmost contributors to a number of medical diseases such as heart diseases, stroke, cancer and diabetes. World Obesity Atlas 2022 forecasted the growth of global obese population to be 16.1% in 2025, accounting for 892 million people which will further reach 1,025 million by 2030 with a healthy growth rate of 17.5% in 2030.  Some of the regional obesity burden estimated by World Obesity Atlas 202...
Read more